Literature DB >> 8748864

Therapy of glioblastoma multiforme: a cumulative experience of 10 years.

A Obwegeser1, M Ortler, M Seiwald, H Ulmer, H Kostron.   

Abstract

PURPOSE: Comparison of the effect of different therapeutic modalities on survival time of patients with glioblastoma multiforme operated on during the last decade (1980-1990). PATIENTS AND METHODS: The records of 157 consecutive patients with the histological diagnosis of glioblastoma multiforme were analysed for survival with respect to age of patients, extent of surgery, influence of re-operation and adjuvant postoperative treatment. The latter included fractionated radiotherapy, chemotherapy (BCNU. CCNU with Vincristine) and photodynamic therapy (PDT).
RESULTS: Analysis of variance showed a significant effect for survival after macroscopically radical surgery (p = 0.005), postoperative radiotherapy (p < 0.001), chemotherapy (p < 0.01). Low age (p < 0.05) and a postoperative Karnofsky performance score (KPS) > or = 60 (p < 0.001) had a positive influence: the site of tumour and pre-operative presence of seizures had no significant influence (p > 0.1) on survival time.
CONCLUSION: We conclude that the current adequate management of glioblastoma multiforme should include surgical resection followed by adjuvant treatment such as radiotherapy and chemotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 8748864     DOI: 10.1007/bf02188776

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  26 in total

Review 1.  The intraarterial route of drug delivery in the chemotherapy of malignant brain tumours.

Authors:  F Loew; L Papavero
Journal:  Adv Tech Stand Neurosurg       Date:  1988

2.  Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.

Authors:  H Naganuma; R Kimurat; A Sasaki; A Fukamachi; H Nukui; K Tasaka
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  Hyperthermia treatment for malignant brain tumors: nursing management during therapy.

Authors:  D K Edwards; T K Stupperich; D M Welsh
Journal:  J Neurosci Nurs       Date:  1991-02       Impact factor: 1.230

4.  [Supratentorial glioma: analysis of clinical and temporal parameters in 163 cases].

Authors:  A Huber; H Beran; A Becherer; N Prosenc; A Witzmann
Journal:  Neurochirurgia (Stuttg)       Date:  1993-11

5.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

6.  The value of reoperation for recurrent glioblastoma.

Authors:  P Dirks; M Bernstein; P J Muller; W S Tucker
Journal:  Can J Surg       Date:  1993-06       Impact factor: 2.089

Review 7.  Chemotherapy for malignant gliomas.

Authors:  P L Kornblith; M Walker
Journal:  J Neurosurg       Date:  1988-01       Impact factor: 5.115

8.  Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation.

Authors:  J Yoshida; Y Kajita; T Wakabayashi; K Sugita
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme.

Authors:  F W Kreth; P C Warnke; R Scheremet; C B Ostertag
Journal:  J Neurosurg       Date:  1993-05       Impact factor: 5.115

10.  Long-term survival in patients with glioblastoma multiforme.

Authors:  K L Chandler; M D Prados; M Malec; C B Wilson
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

View more
  8 in total

1.  [Surgical intervention in patients with malignant glioma].

Authors:  Herwig Kostron; Karl Rössler
Journal:  Wien Med Wochenschr       Date:  2006-06

2.  Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery.

Authors:  Timothy C Ryken; Bruce Frankel; Terrance Julien; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

3.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

4.  ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.

Authors:  M Sam Eljamel; Carol Goodman; Harry Moseley
Journal:  Lasers Med Sci       Date:  2007-10-10       Impact factor: 3.161

5.  Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.

Authors:  Thierry Lesimple; Laurent Riffaud; Didier Frappaz; Mohamed Ben Hassel; Daniel Gédouin; Jacques-Olivier Bay; Claude Linassier; Abderrahmane Hamlat; Gilles Piot; Michel Fabbro; Stéphan Saïkali; Béatrice Carsin; Yvon Guégan
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

6.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.

Authors:  S Cha; E A Knopp; G Johnson; A Litt; J Glass; M L Gruber; S Lu; D Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

7.  Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme.

Authors:  Clifton D Fuller; Mehee Choi; Britta Forthuber; Samuel J Wang; Nancy Rajagiriyil; Bill J Salter; Martin Fuss
Journal:  Radiat Oncol       Date:  2007-07-14       Impact factor: 3.481

8.  Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model.

Authors:  A Obwegeser; R Jakober; H Kostron
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.